SAN DIEGO — Intravenous (IV) administration of the anticonvulsant fosphenytoin is effective as a fast-acting treatment for acute trigeminal neuralgia (TN) exacerbation, new research suggested ...

PAOLI, Pa.-- (BUSINESS WIRE)--Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT (fosphenytoin sodium for injection) for the ...

The New Drug Application (NDA) for IM/IV Captisol-Enabled Fosphenytoin (fosphenytoin sodium and sulfobutylether beta-cyclodextrin sodium for injection; Sedor) has been accepted for review and ...